Biomay AG and Medical University of Vienna provide updates at SMi's inaugural Allergies conference

LONDON, LONDON, UNITED KINGDOM, April 25, 2014 /EINPresswire.com/ -- Biomay AG previously announced that an interim analysis for futility has been successfully completed for an ongoing phase IIb study with its 3rd generation grass pollen allergy vaccine BM32.

In a report published on their website, Rainer Henning, CEO of Biomay AG, commented: “Reaching this milestone is an important step in the validation of our peptide carrier fusion protein vaccine platform. We are now looking forward with great confidence to the final read-out of the study in the fourth quarter of 2014“. * http://bit.ly/1f9QF3d

Delegates will hear more from Dr Henning during his keynote address at SMi’s inaugural conference on Allergies which will take place on 9th and 10th July in Central London. Highlights from the presentation entitled: Advances with Recombinant Allergy Vaccines: The Future of Allergy Immunotherapy, will include comparisons on recombinant and synthetic vaccines, identification of allergy immunotherapy shortcomings and discussions on preclinical efficacy, available clinical results and future clinical impacts.

This will be followed by an exclusive presentation by Rudolf Valenta, Professor for Allergology from Medical University of Vienna, who has worked with Biomay AG in developing their recombinant peptide carrier technology in a keynote address entitled: Passive Immunization with Allergen-Specific lgG

Dr. Henning explains: "Biomay has already initiated a Phase IIb trial, where BM32 will be tested in 180 allergic patients under natural pollen exposure over two pollen seasons. Eleven leading allergy centres across Europe have agreed to participate in this new trial and more than 60 patients have already been enrolled. Results are expected in the fall of 2014."

Attendees this year will hear keynote addresses from an array of experts in the Allergies market including Novartis, MedImmune, GSK, Quintiles and Imperial College London. A snap shot of those who have confirmed their attendance include Danone, Nuvo Research GmbH, Laboratorios Leti, Nutricia Research and Anergis

To download a brochure of the conference, visit the event homepage at www.allergies-event.com

Allergies: Analyse industry developments and the future of allergy therapeutics
9-10 July 2014
Holiday Inn Hotel Regents Park, London UK
www.allergies-event.com

Note to Editor:
SMi's Linkedin Allergies Community has been created for professionals, academia and scientists involved in the allergy industry to discuss diagnosis, novel therapeutics and clinical developments targeted towards the treatment of allergy. To join visit http://linkd.in/OV53jM

About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.

More information can be found at www.smi-online.co.uk

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.